Swine influenza vaccine

Patent metadata

Field	Value
Publication number	US-10626414-B2
Application number	US-201715706896-A
Country	US
Kind code	B2
Filing date	Sep 18, 2017
Priority date	Sep 20, 2016
Publication date	Apr 21, 2020
Grant date	Apr 21, 2020

Abstract

The present invention relates to Equine Herpes Virus (EHV) vectors comprising at least one exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein said exogenous antigen encoding sequence is inserted into an insertion site, preferably ORF70, and said exogenous antigen encoding sequence is operably linked to a promoter sequence, preferably the promoter sequence comprising 4pgG600 (SEQ ID NO:1) or 4pMCP600 (SEQ ID NO:2) or the complementary nucleotide sequences thereof or a functional fragment or a functional derivative thereof or the complementary nucleotide sequences thereof. Furthermore, the present invention relates to methods for immunizing a food producing animal comprising administering to such food producing animal an immunogenic composition comprising embodiments of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal.

First claim

What is claimed is:

1. An EHV-1 RacH vector comprising a first and a second exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein the first exogenous antigen encoding sequence is inserted into ORF70, wherein the ORF70 is modified by deleting an approximately 801 bp portion, wherein the deletion corresponds to a sequence having at least 95% sequence homology with SEQ ID NO: 20, and wherein the second exogenous antigen encoding sequences is inserted into an insertion site, and wherein said exogenous antigen encoding sequences are operably linked to promoters.

2. The EHV-1 RacH vector of claim 1 , wherein the first and/or the second exogenous antigen encoding sequence is an influenza hemagglutinin encoding sequence.

3. The influenza hemagglutinin encoding sequence of claim 2 , wherein the hemagglutinin influenza subtype is H1 and/or H3.

4. The EHV-1 RacH vector of claim 1 , wherein the first and/or the second exogenous antigen encoding sequence encodes a hemagglutinin influenza antigen having at least 95% sequence identity with any one of SEQ ID NOs:26, 27, 28, and 29.

5. The EHV-1 RacH vector of claim 1 , wherein the insertion site of the second exogenous antigen encoding sequence is ORF1/3 or ORF70.

6. The EHV-1 RacH vector of claim 1 , wherein the second exogenous antigen encoding sequence is inserted into ORF1/3.

7. The EHV-1 RacH vector of claim 1 , wherein the ORF70 has a partial deletion, truncation, substitution, or modification, and wherein ORF71 remains functional, and wherein the ORF70 gene product glycoprotein G expression has been abolished.

8. The EHV-1 RacH vector of claim 1 , wherein the EHV-1 RacH vector comprises at least one flanking region with sequence comprising any one of SEQ ID NOs: 13, 14, 15, 16, 17, and 18.

9. The EHV-1 RacH vector of claim 1 , wherein at least one of the promoters is SV40 large T, HCMV and MCMV immediate early gene 1, human elongation factor alpha promoter, baculovirus polyhedrin promoter, or a sequence having at comprising any one of SEQ ID Nos: 1, 2, 3, and 4, or the complementary nucleotide sequences thereof.

10. The EHV-1 RacH vector of claim 1 , wherein at least one of the promoters has at least 95% sequence homology with any one of SEQ ID Nos: 1 and 2 or the complementary nucleotide sequences thereof.

11. The EHV-1 RacH vector of claim 1 , wherein at least one of the promoters comprises a sequence having at least 95% sequence identity with SEQ ID NO: 3 or its compliment.

12. The EHV-1 RacH vector of claim 1 , wherein at least one of the promoters comprises a sequence having at least 95% sequence identity with SEQ ID NO: 4 or its compliment.

13. The EHV-1 RacH vector according to claim 1 , wherein the promotors comprise p430 (SEQ ID NO: 3), and p455 (SEQ ID NO: 4).

14. The EHV-1 RacH vector of claim 1 , wherein the first and the second exogenous antigen encoding sequences are hemagglutinin influenza encoding sequences.

15. The EHV-1 RacH vector of claim 1 , wherein the food producing animals are swine.

16. The EHV-1 RacH vector of claim 1 , wherein the pathogen infecting food producing animals is a Swine influenza A virus.

17. The EHV-1 RacH vector of claim 1 , wherein the first or the second exogenous antigen encoding sequence is a hemagglutinin influenza A antigen encoding sequence having a swine origin.

18. The EHV-1 RacH vector of claim 1 , wherein the first or the second exogenous antigen encoding sequence is a hemagglutinin influenza A antigen encoding sequence having a swine origin, and wherein at least one hemagglutinin influenza A antigen encoding sequence having a swine origin is inserted into ORF70.

19. The EHV-1 RacH vector of claim 1 , wherein the second exogenous antigen encoding sequence is inserted into ORF1/3, wherein the first and/or the second exogenous antigen encoding sequence encodes a hemagglutinin influenza antigen having at least 95% sequence identity with any one of SEQ ID NOs:26, 27, 28, and 29, and wherein at the promoters have at least 95% sequence homology with any one of SEQ ID Nos: 1 and 2 or the complementary nucleotide sequences thereof.

20. An immunogenic composition comprising the EHV-1 RacH vector according to claim 1 .

21. The immunogenic composition of claim 20 , wherein the immunogenic composition is a multivalent vaccine.

22. The immunogenic composition of claim 20 , wherein the immunogenic composition is a bivalent vaccine, tetravalent, hexavalent, or heptavalent vaccine.

23. A DIVA vaccine comprising the EHV-1 RacH vector according to claim 1 and a diagnostic marker for differentiating between infected and vaccinated animals.

24. The DIVA vaccine of claim 23 , wherein the DIVA vaccine is a multivalent vaccine.

25. The DIVA vaccine of claim 23 , wherein the DIVA vaccine is a bivalent vaccine, tetravalent, hexavalent, or heptavalent vaccine.

26. A method for immunizing a food producing animal comprising administering to the food producing animal two or more doses of the immunogenic composition according to claim 20 or the DIVA vaccine according to claim 23 .

27. The method of claim 26 , wherein the food producing animal is swine.

28. The method of claim 26 , wherein said method results in an improvement in at least one efficacy parameter selected from: a reduction in weight loss, a lower virus load in lungs, a reduction in lung lesions, a reduced and/or shortened shedding of virus, a reduced rectal temperature, reduced respiratory symptoms, increased induction of anti-Swine Influenza A virus antibodies, increased induction of neutralizing anti-Swine Influenza A virus antibodies, increased stimulation of T-cells against Swine Influenza A virus, increased stimulation of B-cells against Swine Influenza A virus, and a reduction of pro-inflammatory cytokines, or combinations thereof, in comparison to a food producing animal of a non-immunized control group of the same species, wherein the exogenous antigen encoding sequence encodes viral antigen or a hemagglutinin influenza antigen having at least 95% sequence identity with any one of SEQ ID NOs: 26, 27, 28, and 29.

29. A method for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal, the method comprising administering to the food producing animal a therapeutically effective amount of the immunogenic composition according to claim 20 or the DIVA vaccine according to claim 23 , wherein the exogenous antigen encoding sequence encodes a hemagglutinin influenza antigen having at least 95% sequence identity with any one of SEQ ID NOs: 26, 27, 28, and 29.

30. A method of reducing the virus titers in lungs in a food producing animal, in comparison to a food producing animal of a non-immunized control group of the same species, the method comprising administering to the food producing animal a therapeutically effective amount of the immunogenic composition according to claim 20 or the DIVA vaccine according to claim 23 , wherein the exogenous antigen encoding sequence encodes a viral antigen having at least 95% sequence identity with any one of SEQ ID NOs: 26, 27, 28, and 29.

Assignees

• Boehringer Ingelheim Vetmedica Gmbh

Inventors

• Gallei Andreas
• Mundt Alice
• Nikolin Veljko

Classifications

• A61K39/145

  Orthomyxoviridae, e.g. influenza virus · CPC title

• C12N2760/16171

  Demonstrated in vivo effect · CPC title

• C12N2710/16743

  viral genome or elements thereof as genetic vector · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title